Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26951569 | 0.82 | FFAR4 (0.35) | FFAR4EPHX2 | |
| SCHEMBL13323636 | 0.82 | GABRR1 (0.47) | FFAR4GABRR1GABRR2 | |
| SCHEMBL29343805 | 0.82 | FFAR4 (0.35) | FFAR4EPHX2 | |
| SCHEMBL13323586 | 0.82 | GABRR1 (0.47) | FFAR4GABRR1GABRR2 | |
| SCHEMBL13323626 | 0.79 | CYP1A2 (0.38) | FFAR4 | |
| SCHEMBL27502940 | 0.78 | — | — | |
| SCHEMBL13355407 | 0.78 | — | — | |
| SCHEMBL13323612 | 0.77 | CA1 (0.43) | — | |
| SCHEMBL13323639 | 0.77 | CA1 (0.43) | — | |
| SCHEMBL28741185 | 0.75 | HRH3 (0.33) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343968-B2 | Case of renin inhibitors | MERCK CANADA INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | REN, ACE, AGTR1 | EPHX1 449/4885GAA 165/4885FFAR4 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.